Mark G Lewis

List of Publications by Citations

88 papers	8,140 citations	31 h-index	90 g-index
98 ext. papers	11,434 ext. citations	28.3 avg, IF	5.46 L-index

#	Paper	IF	Citations
88	DNA vaccine protection against SARS-CoV-2 in rhesus macaques. *Science*, **2020**, 369, 806-811	33.3	748
87	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. *New England Journal of Medicine*, **2020**, 383, 1544-1555	59.2	612
86	SARS-CoV-2 infection protects against rechallenge in rhesus macaques. *Science*, **2020**, 369, 812-817	33.3	592
85	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. *Nature*, **2020**, 586, 583-588	50.4	550
84	Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. *Nature*, **2017**, 543, 248-251	50.4	502
83	Correlates of protection against SARS-CoV-2 in rhesus macaques. *Nature*, **2021**, 590, 630-634	50.4	498
82	Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. *Nature*, **2014**, 512, 74-7	50.4	403
81	Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. *Science*, **2016**, 353, 1129-32	33.3	386
80	Animal models for COVID-19. *Nature*, **2020**, 586, 509-515	50.4	377
79	REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. *Science*, **2020**, 370, 1110-1115	33.3	330
78	Rapid development of a DNA vaccine for Zika virus. *Science*, **2016**, 354, 237-240	33.3	284
77	Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. *Science*, **2015**, 349, 320-4	33.3	236
76	Zika viral dynamics and shedding in rhesus and cynomolgus macaques. *Nature Medicine*, **2016**, 22, 1448-1455	36.5	228
75	Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. *Journal of Experimental Medicine*, **2018**, 215, 1571-1588	16.6	212
74	Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. *Nature*, **2016**, 540, 284-287	50.4	183
73	Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. *Nature Medicine*, **2020**, 26, 1694-1700	50.5	176
72	Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. *Nature*, **2018**, 563, 360-364	50.4	155

71	Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys. *Cell*, **2017**, 169, 610-620.e14	56.2	139
70	Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E3413-22	11.5	132
69	Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques. *Cell*, **2020**, 183, 1354-1366.e13	56.2	108
68	SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. *Nature Microbiology*, **2021**, 6, 1188-1198	26.6	105
67	In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. *Cell*, **2021**, 184, 4203-4219.e32	56.2	89
66	TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy. *Science Translational Medicine*, **2018**, 10,	17.5	87
65	Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. *Science*, **2021**, 373, eabj0299	33.3	86
64	Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. *Nature*, **2021**, 594, 553-559	50.4	85
63	Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. *Science Translational Medicine*, **2017**, 9,	17.5	80
62	Type I interferon upregulates Bak and contributes to T cell loss during human immunodeficiency virus (HIV) infection. *PLoS Pathogens*, **2013**, 9, e1003658	7.6	68
61	Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. *Science*, **2019**, 366,	33.3	60
60	Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model		38
59	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. *Science*, **2021**, 374, 1343-1353	33.3	32
58	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. *Nature Immunology* , **2021**, 22, 1306-1315	19.1	32
57	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung.. *Cell*, **2021**,	56.2	24
56	Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates **2021**,		24
55	Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques. *Cell*, **2021**, 184, 3467-3473.e11	56.2	23
54	Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques. *Nature*, **2021**, 596, 423-427	50.4	22

53	Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. *Science*, **2021**, 371,	33.3	22
52	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron.. *Cell*, **2022**,	56.2	22
51	Lack of therapeutic efficacy of an antibody to in SIVmac251-infected rhesus macaques. *Science*, **2019**, 365, 1029-1033	33.3	21
50	Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates **2020**,		20
49	Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters		19
48	Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. *Npj Vaccines*, **2021**, 6, 50	9.5	19
47	Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. *Science Translational Medicine*, **2021**, 13,	17.5	17
46	REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters		15
45	Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates **2021**,		13
44	Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques. *JCI Insight*, **2021**, 6,	9.9	13
43	Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern. *Science Translational Medicine*, **2021**, 13, eabj3789	17.5	13
42	Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	13
41	Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters.. *Med*, **2022**,	31.7	13
40	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron		12
39	Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates **2021**,		12
38	Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	12
37	Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. *Cell*, **2020**, 183, 185-196.e14	56.2	11
36	Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters **2021**,		10

35	Optimization of Non-Coding Regions for a Non-Modified mRNA COVID-19 Vaccine. *Nature*, **2021**,	50.4	9
34	A cautionary perspective regarding the isolation and serial propagation of SARS-CoV-2 in Vero cells. *Npj Vaccines*, **2021**, 6, 83	9.5	9
33	Intradermal-delivered DNA vaccine induces durable immunity mediating a reduction in viral load in a rhesus macaque SARS-CoV-2 challenge model. *Cell Reports Medicine*, **2021**, 2, 100420	18	9
32	A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. *Science Translational Medicine*, **2022**, 14,	17.5	9
31	A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge. *Npj Vaccines*, **2021**, 6, 129	9.5	8
30	Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates **2021**,		8
29	Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants. *Science Translational Medicine*, **2021**, 13, eabj2641	17.5	8
28	Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques **2021**,		8
27	Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates.. *Npj Vaccines*, **2022**, 7, 7	9.5	7
26	Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques. *Nature Communications*, **2021**, 12, 1474	17.4	7
25	New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention and Cure. *Journal of Virology*, **2021**,	6.6	7
24	Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques **2021**,		5
23	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway **2021**,		4
22	A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters **2021**,		4
21	SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys **2021**,		4
20	Optimization of Non-Coding Regions Improves Protective Efficacy of an mRNA SARS-CoV-2 Vaccine in Nonhuman Primates		4
19	Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques. *PLoS Pathogens*, **2021**, 17, e1009701	7.6	4
18	A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates **2021**,		3

17	SARS-CoV-2 receptor binding domain displayed on HBsAg virus-like particles elicits protective immunity in macaques.. *Science Advances*, **2022**, 8, eabl6015	14.3	3
16	Vaccine protection against the SARS-CoV-2 Omicron variant in macaques.. *Cell*, **2022**,	56.2	3
15	Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques. **2022**,		2
14	Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery Against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques. *Journal of Virology*, **2021**, JVI0159921	6.6	2
13	Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates **2021**,		2
12	Synthetic Multiantigen MVA Vaccine COH04S1 Protects Against SARS-CoV-2 in Syrian Hamsters and Non-Human Primates **2021**,		2
11	Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2.. *Npj Vaccines*, **2021**, 6, 156	9.5	2
10	A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques.. *Med*, **2022**,	31.7	1
9	An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine prevents beta variant viral replication in rhesus macaques		1
8	Recapitulation of HIV-1 Env-Antibody Coevolution in Macaques Leading to Neutralization Breadth		1
7	SARS-CoV2 infects pancreatic beta cells in vivo and induces cellular and subcellular disruptions that reflect beta cell dysfunction **2021**,		1
6	New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention and Cure		1
5	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques.. *Science Translational Medicine*, **2022**, eabm4996	17.5	1
4	Development of an Probe to Track SARS-CoV-2 Infection in Rhesus Macaques.. *Frontiers in Immunology*, **2021**, 12, 810047	8.4	1
3	Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters.. *Npj Vaccines*, **2022**, 7, 2	9.5	0
2	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates.. *PLoS Biology*, **2022**, 20, e3001609	9.7	0
1	Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques.. *Npj Vaccines*, **2022**, 7, 53	9.5	0